"Completing enrollment of the ASSURE clinical trial marks another major
milestone for Resverlogix as we aim to demonstrate the efficacy of
RVX-208 in atherosclerotic plague regression," stated Donald McCaffrey,
president and chief executive officer of Resverlogix. "RVX-208
stimulates production of ApoA-I, increasing the functional HDL
particles required for reverse cholesterol transport. We expect to
announce top-line data from ASSURE in H1 2013."

ASSURE is a 26-week, multi-center, double-blind, randomized, parallel
group, placebo-controlled clinical trial led by the Cleveland Clinic.
The primary trial endpoint will be measurement of atheroma volume
reduction from baseline to 26 weeks measured by IVUS. Secondary
objectives for ASSURE are evaluating the safety and tolerability of
RVX-208 and effects of RVX-208 on HDL and non-HDL lipid parameters.
Using IVUS data, we will also assess changes in plaque stability, an
important factor affecting risk of myocardial infarction.

About RVX-208

RVX-208 is a first-in-class, small molecule that inhibits BET
bromodomains. It is currently in clinical study for the treatment of
atherosclerosis. RVX-208 functions by removing atherosclerotic plaque
via reverse cholesterol transport (RCT), the natural process through
which atherosclerotic plaque is transported out of the arteries and
removed from the body by the liver. RVX-208 increases production of
ApoA-I, the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT.
Because they are newly produced, these functional HDL particles are
flat and empty and can efficiently remove plaque and stabilize or
reverse atherosclerotic disease. RVX-208 is currently being evaluated
in phase 2b studies for its ability to reverse and/or stabilize
atherosclerotic disease. The drug candidate also has the potential to
treat other indications, including neurodegenerative disorders.

About Resverlogix

Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company
with an epigenetic platform technology that modulates protein
production. Resverlogix is developing RVX-208, a first-in-class small
molecule for the treatment of atherosclerosis. RVX-208 is the first BET
bromodomain inhibitor in clinical trials. New compounds arising from
Resverlogix's epigenetic drug discovery platform function by inhibiting
BET bromodomains and have the potential to impact multiple diseases
including cancer, autoimmune and neurodegenerative disorders.
Resverlogix's common shares trade on the Toronto Stock Exchange (TSX:
RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as
defined under applicable Canadian securities legislation, that are not
based on historical fact, including without limitation statements
containing the words "believes", "anticipates", "plans", "intends",
"will", "should", "expects", "continue", "estimate", "forecasts" and
other similar expressions. In particular, this news release includes
forward looking information relating to research and development
activities and the potential role of RVX-208 in the treatment of
atherosclerosis. Our actual results, events or developments could be
materially different from those expressed or implied by these
forward-looking statements. We can give no assurance that any of the
events or expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and risk
factors including but not limited to those associated with the success
of research and development programs, clinical trial programs including
possible delays in patient recruitment, the regulatory approval
process, competition, securing and maintaining corporate alliances,
market acceptance of the Company's products, the availability of
government and insurance reimbursements for the Company's products, the
strength of intellectual property, financing capability, the potential
dilutive effects of any financing, reliance on subcontractors and key
personnel and additional assumptions and risk factors discussed in our
Annual Information Form and most recent MD&A which are incorporated
herein by reference and are available through SEDAR at www.sedar.com.
The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of the
date hereof. The Company disclaims any intention and has no obligation
or responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.